Wolverine Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Wolverine Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-40,265	Closed	-$5.31M	–	1879
2025 Q1	$5.31M	Buy	+40,265	New	+$5.02M	0.06%	289
2021 Q1	–	Sell	-11,222	Closed	-$356K	–	2314
2020 Q4	$356K	Buy	+11,222	New	+$295K	﹤0.01%	948

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wolverine Asset Management's ITCI Position: Q2 2025 in Review

Wolverine Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 40,265 shares — an estimated $5.31M sold.

Wolverine Asset Management first reported a position in ITCI in Q4 2020 and held it in 2 quarters. The position peaked at $5.31M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Wolverine Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Wolverine Asset Management sold 40,265 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $5.31M.
Wolverine Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 2 quarters.
Wolverine Asset Management's Intra-Cellular Therapies Inc. position peaked at $5.31M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Wolverine Asset Management's 13F filing for Q2 2025, filed 4 Aug 2025.